Valentina Del Dotto

@unibo.it

Dipartimento di Scienze Biomediche e NeuroMotorie (DIBINEM)
University of Bologna

EDUCATION

2015: PhD in Cellular and Molecular Biology, University of Bologna
Thesis title: “OPA1 isoforms and protein domains in the rescue of mitochondrial dysfunctions”.

2011: Master’s Degree in Pharmaceutical Biotechnology, University of Bologna
Thesis title: “Effect of genotoxic and hypotoxic stress on the modulation of mitochondrial biogenesis”.

2009: Bachelor’s Degree in Biotechnology, University of Bologna.
28

Scopus Publications

Scopus Publications

  • Pathogenic Mechanisms in Cervical Cancer: Energy Metabolism, Hypoxia and Therapy
    Valentina Giorgio, Valentina Del Dotto, Martina Grandi, Silvia Grillini, Giancarlo Solaini, et al.
    Life, 2026
    Cervical cancer has a high incidence and mortality, and is one of the leading causes of cancer-related deaths among women worldwide. The infection with high-risk subtypes of the human papillomavirus (HPV) represents a crucial factor in the development of precancerous lesions. HPV oncoproteins target multiple host factors to promote uncontrolled cellular proliferation, genomic instability, profound metabolic reprogramming, resistance to apoptosis and immune evasion. Thus, cervical carcinogenesis involves metabolic reprogramming in patient cells, such as enhanced aerobic glycolysis, and altered glutamine, lipid and mitochondrial metabolism, which collectively support the bioenergetic and biosynthetic demands of cancer cells. Cancer cells also activate several mechanisms to adapt and survive under hypoxic/anoxic conditions. The mechanisms underlying cervical carcinogenesis often involve non-coding RNAs. This review aims at summarizing the mechanisms and factors involved in the development and progression of cervical cancer following HPV infection, and offers an overview of the available therapies that have been developed for this disease.
  • Bioenergetics of cancer cells: insights into the Warburg effect and regulation of ATP synthase
    Valentina Del Dotto, Silvia Grillini, Riccardo Righetti, Martina Grandi, Valentina Giorgio, et al.
    Molecular Medicine, 2025
    The study reported here offers new insights into the metabolic changes associated with the Warburg effect (i.e. aerobic glycolysis) in cancer cells and into the possible role of IF1, the endogenous inhibitor of ATP synthase that preserves cellular energy when it works in reverse, hydrolyzing ATP. We investigated biochemical and main bioenergetic parameters in cell lines derived from three human tumors: osteosarcoma (143B), colon carcinoma (HCT116), and cervix carcinoma (HeLa). The combination analysis of cellular glucose consumption, lactate production, ATP-linked respiration rate, ATP level, cell culture medium acidification rate, and ROS level demonstrates that aerobic glycolysis is differently expressed by the three different types of tumor cells, although all cell types exhibited a Warburg phenotype. The superoxide anion level was found to be lower in HCT116 cells, which showed the highest ratio between oxidative phosphorylation and glycolysis rates, while ROS level was similar in all cells examined, suggesting that mitochondria in HCT116 are very efficient in both energy production and limiting their oxidative stress. Additionally, IF1 KD cells of all kinds of tumor showed higher level of ROS compared to their related IF1-expressing cells. Most of the results reported here clearly demonstrate that aerobic glycolysis is completely independent on both the level of IF1 and the IF1/ATP synthase ratio, excluding the contribution of an IF1-dependent mechanism in the metabolic shift of cancer cells towards glycolysis. Indeed, the study provides a detailed analysis of the bioenergetics of tumor cells exhibiting very different IF1/ATP synthase ratios and shows that IF1 KD cells of all tumor types had a higher level of ROS than their related IF1-expressing cells. Overall, the comprehensive picture of tumor cell bioenergetics would facilitate the identification of appropriate drugs for targeted tumor treatments, such as ATP synthase-IF1 immunotherapy that would strongly limit cellular resistance to severe hypoxia or anoxia, where IF1 plays an effective critical role.
  • Lipidomics reveals the reshaping of the mitochondrial phospholipid profile in cells lacking OPA1 and mitofusins
    Andrea Castellaneta, Ilario Losito, Vito Porcelli, Serena Barile, Alessandra Maresca, et al.
    Journal of Lipid Research, 2024
  • Genetic variants affecting NQO1 protein levels impact the efficacy of idebenone treatment in Leber hereditary optic neuropathy
    Serena Jasmine Aleo, Valentina Del Dotto, Martina Romagnoli, Claudio Fiorini, Giada Capirossi, et al.
    Cell Reports Medicine, 2024
  • Variants in Human ATP Synthase Mitochondrial Genes: Biochemical Dysfunctions, Associated Diseases, and Therapies
    Valentina Del Dotto, Francesco Musiani, Alessandra Baracca, Giancarlo Solaini
    International Journal of Molecular Sciences, 2024
    Mitochondrial ATP synthase (Complex V) catalyzes the last step of oxidative phosphorylation and provides most of the energy (ATP) required by human cells. The mitochondrial genes MT-ATP6 and MT-ATP8 encode two subunits of the multi-subunit Complex V. Since the discovery of the first MT-ATP6 variant in the year 1990 as the cause of Neuropathy, Ataxia, and Retinitis Pigmentosa (NARP) syndrome, a large and continuously increasing number of inborn variants in the MT-ATP6 and MT-ATP8 genes have been identified as pathogenic. Variants in these genes correlate with various clinical phenotypes, which include several neurodegenerative and multisystemic disorders. In the present review, we report the pathogenic variants in mitochondrial ATP synthase genes and highlight the molecular mechanisms underlying ATP synthase deficiency that promote biochemical dysfunctions. We discuss the possible structural changes induced by the most common variants found in patients by considering the recent cryo-electron microscopy structure of human ATP synthase. Finally, we provide the state-of-the-art of all therapeutic proposals reported in the literature, including drug interventions targeting mitochondrial dysfunctions, allotopic gene expression- and nuclease-based strategies, and discuss their potential translation into clinical trials.
  • The pro-oncogenic protein IF1 does not contribute to the Warburg effect and is not regulated by PKA in cancer cells
    Gianluca Sgarbi, Riccardo Righetti, Valentina Del Dotto, Silvia Grillini, Valentina Giorgio, et al.
    Biochimica Et Biophysica Acta Molecular Basis of Disease, 2024
  • Methyl carbamates of phosphatidylethanolamines and phosphatidylserines reveal bacterial contamination in mitochondrial lipid extracts of mouse embryonic fibroblasts
    Andrea Castellaneta, Vito Porcelli, Ilario Losito, Serena Barile, Alessandra Maresca, et al.
    Scientific Reports, 2023
    The occurrence of methyl carbamates of phosphatidylethanolamines and phosphatidylserines in the lipid extract of mitochondria obtained from mouse embryonic fibroblasts was ascertained by hydrophilic interaction liquid chromatography with electrospray ionization single and multi-stage mass spectrometry, performed using sinergically a high resolution (quadrupole-Orbitrap) and a low resolution (linear ion trap) spectrometer. Two possible routes to the synthesis of methyl carbamates of phospholipids were postulated and evaluated: (i) a chemical transformation involving phosgene, occurring as a photooxidation by-product in the chloroform used for lipid extraction, and methanol, also used for the latter; (ii) an enzymatic methoxycarbonylation reaction due to an accidental bacterial contamination, that was unveiled subsequently on the murine mitochondrial sample. A specific lipid extraction performed on a couple of standard phosphatidyl-ethanolamines/-serines, based on purposely photo-oxidized chloroform and deuterated methanol, indicated route (i) as negligible in the specific case, thus highlighting the enzymatic route related to bacterial contamination as the most likely source of methyl carbamates. The unambiguous recognition of the latter might represent the starting point toward a better understanding of their generation in biological systems and a minimization of their occurrence when an artefactual formation is ascertained.
  • The Pro-Oncogenic Protein IF1 Promotes Proliferation of Anoxic Cancer Cells during Re-Oxygenation
    Riccardo Righetti, Silvia Grillini, Valentina Del Dotto, Anna Costanzini, Francesca Liuzzi, et al.
    International Journal of Molecular Sciences, 2023
    Cancer cells overexpress IF1, the endogenous protein that inhibits the hydrolytic activity of ATP synthase when mitochondrial membrane potential (ΔμH+) falls, as in ischemia. Other roles have been ascribed to IF1, but the associated molecular mechanisms are still under debate. We investigated the ability of IF1 to promote survival and proliferation in osteosarcoma and colon carcinoma cells exposed to conditions mimicking ischemia and reperfusion, as occurs in vivo, particularly in solid tumors. IF1-silenced and parental cells were exposed to the FCCP uncoupler to collapse ΔμH+ and the bioenergetics of cell models were validated. All the uncoupled cells preserved mitochondrial mass, but the implemented mechanisms differed in IF1-expressing and IF1-silenced cells. Indeed, the membrane potential collapse and the energy charge preservation allowed an increase in both mitophagy and mitochondrial biogenesis in IF1-expressing cells only. Interestingly, the presence of IF1 also conferred a proliferative advantage to cells highly dependent on oxidative phosphorylation when the uncoupler was washed out, mimicking cell re-oxygenation. Overall, our results indicate that IF1, by allowing energy preservation and promoting mitochondrial renewal, can favor proliferation of anoxic cells and tumor growth. Therefore, hindering the action of IF1 may be promising for the therapy of tumors that rely on oxidative phosphorylation for energy production.
  • Rapamycin rescues mitochondrial dysfunction in cells carrying the m.8344A > G mutation in the mitochondrial tRNALys
    Mariantonietta Capristo, Valentina Del Dotto, Concetta Valentina Tropeano, Claudio Fiorini, Leonardo Caporali, et al.
    Molecular Medicine, 2022
    Background Myoclonus, Epilepsy and Ragged-Red-Fibers (MERRF) is a mitochondrial encephalomyopathy due to heteroplasmic mutations in mitochondrial DNA (mtDNA) most frequently affecting the tRNALys gene at position m.8344A > G. Defective tRNALys severely impairs mitochondrial protein synthesis and respiratory chain when a high percentage of mutant heteroplasmy crosses the threshold for full-blown clinical phenotype. Therapy is currently limited to symptomatic management of myoclonic epilepsy, and supportive measures to counteract muscle weakness with co-factors/supplements. Methods We tested two therapeutic strategies to rescue mitochondrial function in cybrids and fibroblasts carrying different loads of the m.8344A > G mutation. The first strategy was aimed at inducing mitochondrial biogenesis directly, over-expressing the master regulator PGC-1α, or indirectly, through the treatment with nicotinic acid, a NAD+ precursor. The second was aimed at stimulating the removal of damaged mitochondria through prolonged rapamycin treatment. Results The first approach slightly increased mitochondrial protein expression and respiration in the wild type and intermediate-mutation load cells, but was ineffective in high-mutation load cell lines. This suggests that induction of mitochondrial biogenesis may not be sufficient to rescue mitochondrial dysfunction in MERRF cells with high-mutation load. The second approach, when administered chronically (4 weeks), induced a slight increase of mitochondrial respiration in fibroblasts with high-mutation load, and a significant improvement in fibroblasts with intermediate-mutation load, rescuing completely the bioenergetics defect. This effect was mediated by increased mitochondrial biogenesis, possibly related to the rapamycin-induced inhibition of the Mechanistic Target of Rapamycin Complex 1 (mTORC1) and the consequent activation of the Transcription Factor EB (TFEB). Conclusions Overall, our results point to rapamycin-based therapy as a promising therapeutic option for MERRF.
  • Pathological mitophagy disrupts mitochondrial homeostasis in Leber's hereditary optic neuropathy
    Alberto Danese, Simone Patergnani, Alessandra Maresca, Camille Peron, Andrea Raimondi, et al.
    Cell Reports, 2022
  • Dominant Optic Atrophy (DOA): Modeling the Kaleidoscopic Roles of OPA1 in Mitochondrial Homeostasis
    Valentina Del Dotto, Valerio Carelli
    Frontiers in Neurology, 2021
  • Author Correction: Calcium mishandling in absence of primary mitochondrial dysfunction drives cellular pathology in Wolfram Syndrome (Scientific Reports, (2020), 10, 1, (4785), 10.1038/s41598-020-61735-3)
    Chiara La Morgia, Alessandra Maresca, Giulia Amore, Laura Ludovica Gramegna, Michele Carbonelli, et al.
    Scientific Reports, 2020
  • Calcium mishandling in absence of primary mitochondrial dysfunction drives cellular pathology in Wolfram Syndrome
    Chiara La Morgia, Alessandra Maresca, Giulia Amore, Laura Ludovica Gramegna, Michele Carbonelli, et al.
    Scientific Reports, 2020
  • Drug repositioning as a therapeutic strategy for neurodegenerations associated with OPA1 mutations
    Serena J Aleo, Valentina Del Dotto, Mario Fogazza, Alessandra Maresca, Tiziana Lodi, et al.
    Human Molecular Genetics, 2020
  • Expanding and validating the biomarkers for mitochondrial diseases
    Alessandra Maresca, Valentina Del Dotto, Martina Romagnoli, Chiara La Morgia, Lidia Di Vito, et al.
    Journal of Molecular Medicine, 2020
  • ATPase Domain AFG3L2 Mutations Alter OPA1 Processing and Cause Optic Neuropathy
    Leonardo Caporali, Stefania Magri, Andrea Legati, Valentina Del Dotto, Francesca Tagliavini, et al.
    Annals of Neurology, 2020
  • Metabolomics hallmarks OPA1 variants correlating with their in vitro phenotype and predicting clinical severity
    Juan Manuel Chao de la Barca, Mario Fogazza, Michela Rugolo, Stéphanie Chupin, Valentina Del Dotto, et al.
    Human Molecular Genetics, 2020
  • SSBP1 mutations cause mtDNA depletion underlying a complex optic atrophy disorder
    Valentina Del Dotto, Farid Ullah, Ivano Di Meo, Pamela Magini, Mirjana Gusic, et al.
    Journal of Clinical Investigation, 2020
  • DNMT1 mutations leading to neurodegeneration paradoxically reflect on mitochondrial metabolism
    Alessandra Maresca, Valentina Del Dotto, Mariantonietta Capristo, Emanuela Scimonelli, Francesca Tagliavini, et al.
    Human Molecular Genetics, 2020
  • Mitochondrial mass assessment in a selected cell line under different metabolic conditions
    Anna Costanzini, Gianluca Sgarbi, Alessandra Maresca, Valentina Del Dotto, Giancarlo Solaini, et al.
    Cells, 2019
  • Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models
    Valentina Del Dotto, Mario Fogazza, Francesco Musiani, Alessandra Maresca, Serena J. Aleo, et al.
    Biochimica Et Biophysica Acta Molecular Basis of Disease, 2018
  • OPA1: How much do we know to approach therapy?
    Valentina Del Dotto, Mario Fogazza, Guy Lenaers, Michela Rugolo, Valerio Carelli, et al.
    Pharmacological Research, 2018
  • Eight human OPA1 isoforms, long and short: What are they for?
    Valentina Del Dotto, Mario Fogazza, Valerio Carelli, Michela Rugolo, Claudia Zanna
    Biochimica Et Biophysica Acta Bioenergetics, 2018
  • Peculiar combinations of individually non-pathogenic missense mitochondrial DNA variants cause low penetrance Leber’s hereditary optic neuropathy
    Leonardo Caporali, Luisa Iommarini, Chiara La Morgia, Anna Olivieri, Alessandro Achilli, et al.
    Plos Genetics, 2018
  • Incomplete penetrance in mitochondrial optic neuropathies
    Leonardo Caporali, Alessandra Maresca, Mariantonietta Capristo, Valentina Del Dotto, Francesca Tagliavini, et al.
    Mitochondrion, 2017